LGC
EW icon

Laurel Grove Capital’s Edwards Lifesciences EW Stock Holding History

Laurel Grove Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$296K Hold
5,100
– – 0.15% 88
2018
Q2 		$247K Hold
5,100
– – 0.13% 90
2018
Q1 		$237K Buy
+5,100
New +$221K 0.13% 92
2017
Q3 		– Sell
-5,100
Closed -$201K – 103
2017
Q2 		$201K Buy
+5,100
New +$186K 0.11% 96

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Laurel Grove Capital's EW Position: Q3 2018 in Review

Laurel Grove Capital held its Edwards Lifesciences (EW) position steady in Q3 2018 at 5,100 shares worth $296K. The position accounts for 0.15% of the portfolio, ranked #88.

Laurel Grove Capital first reported a position in EW in Q2 2017 and has held it in 4 quarters since. 853 funds tracked by Wall St. Rank hold EW as of Q3 2018.

  • Laurel Grove Capital held 5,100 shares of Edwards Lifesciences worth $296K as of Q3 2018.
  • Laurel Grove Capital left its Edwards Lifesciences share count unchanged in Q3 2018.
  • Edwards Lifesciences made up 0.15% of Laurel Grove Capital's portfolio in Q3 2018, its #88 holding.
  • Laurel Grove Capital first reported a position in Edwards Lifesciences in Q2 2017 and has held it in 4 quarters since.
  • 853 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2018.

Based on Laurel Grove Capital's 13F filing for Q3 2018, filed 12 Oct 2018.